CIPLA vs MANKIND: Stock Comparison
CIPLA is the larger company by market capitalisation. CIPLA shows a lower P/E, a higher dividend yield and lower leverage, while MANKIND PHARMA shows a higher ROE, faster revenue growth and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
CIPLA leads 7; MANKIND leads 6 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | CIPLA | MANKIND |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | CIPLA | MANKIND |
|---|---|---|
| Live Price | ₹1,385 | ₹2,327.9 |
| Day Change | -0.7% | -1.73% |
| Volume | 13.26 L | 1.22 L |
| 52-Week High | ₹1,673 | ₹2,674 |
| 52-Week Low | ₹1,165.7 | ₹1,909.7 |
| Distance from 52W High | -17.21% | -12.94% |
Valuation
| Metric | CIPLA | MANKIND |
|---|---|---|
| Market Cap | ₹1.12 L Cr | ₹96,168 Cr |
| P/E Ratio | 33.86x | 47.96x |
| P/B Ratio | 3.32x | 6.03x |
| EPS | ₹10.67 | ₹13.52 |
| Book Value | ₹427.31 | ₹401 |
| Dividend Yield | 0.94% | 0% |
Growth
| Metric | CIPLA | MANKIND |
|---|---|---|
| Revenue Growth (TTM YoY) | -2.1% | 11.8% |
| EPS Growth (TTM YoY) | -54.6% | 31.7% |
| Qtr Sales Growth | -28.68% | -26.46% |
| Qtr Profit Growth | 9.75% | -2.72% |
Profitability & Leverage
| Metric | CIPLA | MANKIND |
|---|---|---|
| ROE | 10.28% | 11.7% |
| ROCE | 10.09% | 11.17% |
| Net Margin | 13.96% | 13.34% |
| Operating Margin | 24.53% | 20.73% |
| Debt to Equity | 0x | 0.38x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | CIPLA | MANKIND |
|---|---|---|
| Promoter Holding | 9.17% | 72.63%▼ 0.03 pp |
| FII Holding | 20.21%▼ 2.35 pp | 9.45%▼ 0.79 pp |
| DII Holding | 34.63%▲ 2.66 pp | 15.39%▲ 0.93 pp |
| Public Holding | 15.94%▼ 0.31 pp | 2.53%▼ 0.11 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: CIPLA and MANKIND PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.